Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MT1980 in Healthy Volunteers
NCT05429840Phase 1Completed
- Sponsor
- Monument Therapeutics
- Start
- Jun 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of MT1980 in neuroinflammation (5 arms), sponsored by Monument Therapeutics. Primary endpoint: Treatment-related adverse events. Started Jun 2022; status: completed.
02
Drugs
MT1980
03
Conditions
neuroinflammation
Beyond the preview
Go deeper on NCT05429840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05429840.